相关实验视频

Updated: Jun 20, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

多塞塔塞尔加S-1与多塞塔塞尔加capecitabine作为先进乳腺癌患者的第一线治疗:一个前性随机二期研究

Nilupai Abudureheiyimu¹, Yun Wu¹, Qing Li¹

¹Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Journal of the National Cancer Center

|July 22, 2024

概括

多塞塔克塞尔/S-1 (TS) 和多塞塔克塞尔/capecitabine (TX) 在晚期乳腺癌中表现出类似的疗效. TS的手脚综合征较少,提供了可行的替代治疗选择.

科学领域:

在瘤学瘤学.
临床药理学临床药理学
癌症治疗方法癌症治疗方法

背景情况:

晚期乳腺癌需要有效的第一线化疗.
多塞塔塞尔与口服皮里米丁 (S-1或capecitabine) 结合使用是治疗选择.
将多塞塔塞尔/S-1 (TS) 与多塞塔塞尔/capecitabine (TX) 进行比较对于治疗选择至关重要.

研究的目的:

评估和比较多塞塔克塞尔/S-1 (TS) 与多塞塔克塞尔/capecitabine (TX) 作为先进乳腺癌的第一线治疗的疗效和安全性.
为了确定两种治疗方案之间的无进展生存 (PFS) 和总生存 (OS) 的差异.
评估安全概况并确定不良事件中的任何显著差异.

主要方法:

一项随机对照试验,涉及111名患有晚期转移性乳腺癌的患者.
患者被分配到TS组 (n=54) 或TX组 (n=57) 进行一线化疗.
无进展生存 (PFS) 是主要终点;整体生存 (OS) 和不良事件也受到监测.

主要成果:

在TS和TX组中,PFS的中位数与TS和TX组相似 (9.0与7.4个月,P=0.365).
平均寿命也相当于 (40.2个月与41.3个月,P=0.976).
手脚综合征在TX组明显高 (38.6%对7.4%,P=0.001),而腹和升高的AST/ALT水平在TS组更频繁.

结论:

两种TS和TX方案在一线先进乳腺癌治疗中都显示出可比的疗效和安全性.
TS疗法具有良好的安全性,并减少了严重手脚综合征的发生,这使其成为一种有价值的替代方案.
建议进行进一步的现实研究,以确认TS疗程的长期疗效和安全性.

关键词:

晚期乳腺癌是什么晚期乳腺癌卡佩西塔宾 (Capecitabine) 是一种药物.多塞塔克塞尔 (Docetaxel) 是一种药物.维持疗法是一种维持疗法.在S-1中,S-1是S-1.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...